Last updated 2026-08-06
- Raised $5M PIPE led by SIBF VC, Jan 2021
- Raised $14M PIPE, Dec 2020
- Raised $5M PIPE, Aug 2018
Total raised
$25.6M
Last: Public Offering 2026-03
Stage
Public
Founded
2008
Headcount
49
HQ
Haifa, Israel
Sector
Health Tech & Life Sciences
About
Bonus BioGroup is an advanced clinical-stage biotechnology company developing 'next-generation' therapies for a variety of indications in the regenerative medicine field. The company leverages its extensive knowledge and expertise to establish a unique technological platform that underpins the development of its leading product candidates, BonoFill and MesenCure. Bonus BioGroup's mission is to develop and deliver safe, effective, and affordable tissue engineering and cell therapy products to address severe conditions representing multi-billion-dollar markets with limited treatment options. The company is currently listed on the Tel Aviv Stock Exchange (TASE: BONS) and is pursuing a dual listing on Nasdaq.
Funding history · 5 rounds · $25.6M total
2021-01
PIPE
$5.0M
★ SIBF VC
2020-12
PIPE
$14.0M
2018-08
PIPE
$5.0M
2014-12
Grant
$1.6M
2012-01
Follow-on PO
Undisclosed
Headcount over time
From 28 (2019-08) to 42 (2025-12) · +14 (+50%) · 41 points · source: Finder history + radar grounding
Q&A
- What is Bonus BioGroup's primary focus?
- Bonus BioGroup is a clinical-stage biotechnology company that develops next-generation cell therapy solutions for regenerative medicine.
- When was Bonus BioGroup founded?
- Bonus BioGroup was founded in 2008.
- What is the current employee count for Bonus BioGroup?
- Bonus BioGroup has 11-50 employees.
- What is the total amount of funding Bonus BioGroup has raised to date?
- Bonus BioGroup has raised a total of $57,450,000.
- What was Bonus BioGroup's most recent funding round?
- Bonus BioGroup secured a Public Offering in March 2026, raising $18,750,000.
- Which investors participated in Bonus BioGroup's PIPE round in January 2021?
- The PIPE round in January 2021 included SIBF VC.
- What was the amount raised in Bonus BioGroup's Public Offering in May 2025?
- Bonus BioGroup raised $20,000,000 in a Public Offering in May 2025.
- What was the amount raised in Bonus BioGroup's Public Offering in March 2026?
- Bonus BioGroup raised $15,000,000 in a Public Offering in March 2026, with D. Boral Capital as the sole bookrunner.
Team · 12
Dr. Shai Meretzki
Founder · Founder & CEO
Meital Enbar
VP of Finance
Dror Ben David
Chief Operations Officer
Atara Novak
VP, Research & Development
Corinne Chemouny
VP, Quality Assurance
Tomer Bronshtein
VP, Innovation & Corporate Development
Gil Shapira
Director
Alon Ariel
Director
Edwin M. Horwitz
Professor of Cell Therapy and Pediatric Medicine
Nimrod Rozen
Orthopedic Surgeon and Researcher
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2B
Highlights
Patents
Tags
biotechnologyregenerative-medicinebone-regenerationcell-therapytissue-engineeringorthopedicsmedical-technologiesstem-cellspersonalized-medicine
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | bonus-bio.com |
|---|---|
| linkedin.com/company/14822062 |
Identifiers & details
| Legal name | Bonus Biogroup Ltd. |
|---|---|
| Founded | 2008 |
| Employees (exact) | 49 |
Radar intelligence
Patents
| EPO | 1 |
|---|
Web history (Wayback)
| Domain | bonus-bio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 520039777 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 1981-10-04 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2002 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | פארק מתם 20 חיפה |